JP2024517477A - 黒色腫を治療するためのリプレチニブ - Google Patents

黒色腫を治療するためのリプレチニブ Download PDF

Info

Publication number
JP2024517477A
JP2024517477A JP2023569861A JP2023569861A JP2024517477A JP 2024517477 A JP2024517477 A JP 2024517477A JP 2023569861 A JP2023569861 A JP 2023569861A JP 2023569861 A JP2023569861 A JP 2023569861A JP 2024517477 A JP2024517477 A JP 2024517477A
Authority
JP
Japan
Prior art keywords
patient
ripretinib
daily
melanoma
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517477A5 (https=
Inventor
ソト，ロドリゴ・ルイス
スー，イン
Original Assignee
デシフェラ・ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デシフェラ・ファーマシューティカルズ，エルエルシー filed Critical デシフェラ・ファーマシューティカルズ，エルエルシー
Publication of JP2024517477A publication Critical patent/JP2024517477A/ja
Publication of JP2024517477A5 publication Critical patent/JP2024517477A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2023569861A 2021-05-12 2022-05-10 黒色腫を治療するためのリプレチニブ Pending JP2024517477A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163187903P 2021-05-12 2021-05-12
US63/187,903 2021-05-12
US202163231384P 2021-08-10 2021-08-10
US63/231,384 2021-08-10
US202263313570P 2022-02-24 2022-02-24
US63/313,570 2022-02-24
PCT/US2022/028456 WO2022240799A1 (en) 2021-05-12 2022-05-10 Ripretinib for treating melanoma

Publications (2)

Publication Number Publication Date
JP2024517477A true JP2024517477A (ja) 2024-04-22
JP2024517477A5 JP2024517477A5 (https=) 2025-05-20

Family

ID=81854549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569861A Pending JP2024517477A (ja) 2021-05-12 2022-05-10 黒色腫を治療するためのリプレチニブ

Country Status (6)

Country Link
US (1) US20240122906A1 (https=)
EP (1) EP4337201A1 (https=)
JP (1) JP2024517477A (https=)
AU (1) AU2022273288A1 (https=)
CA (1) CA3218436A1 (https=)
WO (1) WO2022240799A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118416236A (zh) * 2018-01-31 2024-08-02 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
TWI878335B (zh) * 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法

Also Published As

Publication number Publication date
CA3218436A1 (en) 2022-11-17
US20240122906A1 (en) 2024-04-18
EP4337201A1 (en) 2024-03-20
WO2022240799A1 (en) 2022-11-17
AU2022273288A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
AU2024205010B2 (en) CSF1R inhibitors for use in treating cancer
US12213968B2 (en) Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
US10512651B2 (en) Inhibition of MK2 in the treatment of cancer
TW202136258A (zh) １—（４—溴—５—（１—乙基—７—（甲胺基）—２—側氧基—１，２—二氫—１，６—萘啶—３—基）—２—氟苯基）—３—苯脲組合物
US20240122906A1 (en) Methods of treating melanoma with ripretinib
US20210275518A1 (en) Methods of using rebastinib in the treatment of disorders
CN117693341A (zh) 用于治疗黑素瘤的瑞普替尼
CA3163051C (en) Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
EA052090B1 (ru) Композиции 1-(4-бром-5-(1-этил-7-(метиламино)-2-оксо-1,2-дигидро-1,6-нафтиридин-3-ил)-2-фторфенил)-3-фенилмочевины
HK40107869A (en) Amorphous kinase inhibitor formulations and methods of use thereof
EA052336B1 (ru) Препараты аморфного ингибитора киназы и способы их применения
EA046076B1 (ru) Ингибиторы csf1r для применения в лечении рака

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250512